April's Must-Watch Biotech Stock
From revolutionary science to the impact of Obamacare, every week The Motley Fool's health-care team sits down to discuss the most fascinating developments across the health-care industry and their implications for long-term investors. In this week's edition, the team talks about the disruptive potential of a new iPhone app, as well as an FDA inquiry that could have negative implications for some of the pharmaceutical industry's biggest players. In addition, our analysts dive into some of the stocks making big moves over the past week and discuss companies on their radar for the near future.
In the following segment, health-care analyst David Williamson discusses a stock to watch in the coming weeks: Sarepta. The biotech has a number of critical catalysts that could propel the stock to new highs or send it plunging lower. Find out why investors need to have Sarepta on their radar going into an important FDA decision in April.
And after watching the video, see what macro trend Warren Buffett was referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: "What's Really Eating at America's Competitiveness." You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.
The relevant video segment can be found between 12:43 and 14:21.
The article April's Must-Watch Biotech Stock originally appeared on Fool.com.
David Williamson has no position in any stocks mentioned. Follow him on Twitter: @MotleyDavid. Max Macaluso, Ph.D., and The Motley Fool also have no position in any of the stocks mentioned. Brenton Flynn owns shares of Sarepta Therapeutics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
